Japan Approves AstraZeneca's Soliris (Eculizumab) For Expanded Use For Refractory Generalized Myasthenia Gravis In Pediatric Patients Who Previously Failed Immunosuppressive Treatment, With Unresolved Disease Symptoms
Portfolio Pulse from Benzinga Newsdesk
Japan has approved AstraZeneca's Soliris (Eculizumab) for expanded use in treating refractory generalized Myasthenia Gravis in pediatric patients who previously failed immunosuppressive treatment. Soliris is the first and only targeted therapy approved for the treatment of children and adolescents with gMG in Japan.
August 24, 2023 | 9:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Soliris has been approved for expanded use in Japan, potentially increasing the company's market share and revenues in the region.
The approval of Soliris for expanded use in Japan opens up a new market for AstraZeneca, potentially leading to increased sales and revenues. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100